Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-cash Items (2023 - 2025)

Historic Non-cash Items for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $19.9 million.

  • Contineum Therapeutics' Non-cash Items fell 4910.16% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 4910.16%. This contributed to the annual value of $21.5 million for FY2024, which is 4421.01% up from last year.
  • Per Contineum Therapeutics' latest filing, its Non-cash Items stood at $19.9 million for Q3 2025, which was down 4910.16% from $2.6 million recorded in Q2 2025.
  • Contineum Therapeutics' Non-cash Items' 5-year high stood at $39.0 million during Q3 2024, with a 5-year trough of $1.9 million in Q2 2024.
  • Its 3-year average for Non-cash Items is $16.1 million, with a median of $17.4 million in 2023.
  • Its Non-cash Items has fluctuated over the past 5 years, first soared by 4421.01% in 2024, then plummeted by 9181.23% in 2025.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Non-cash Items stood at $14.9 million in 2023, then soared by 44.21% to $21.5 million in 2024, then dropped by 7.51% to $19.9 million in 2025.
  • Its last three reported values are $19.9 million in Q3 2025, $2.6 million for Q2 2025, and $2.2 million during Q1 2025.